SciSparc
Specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The company has four drug candidates in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease and Agitation, Autism Spectrum Disorder, and two in pre-clinical studies for Status Epilepticus and Chronic Pain.
History
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The company's pipeline includes four drug candidates in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease and Agitation, Autism Spectrum Disorder, and two in pre-clinical studies for Status Epilepticus and Chronic Pain.
Recent events
SciSparc rebrands and changes its company name[4]
Reported:
SciSparc announced that it had changed its company name from Therapix Biosciences Ltd. to SciSparc Ltd. as part of a rebranding that also included a new logo and share symbol.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/scisparc · Editorial policy · How profiles are compiled